GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (HKSE:00950) » Definitions » ROC %

Lee's Pharmaceutical Holdings (HKSE:00950) ROC % : 3.75% (As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Lee's Pharmaceutical Holdings ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Lee's Pharmaceutical Holdings's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was 3.75%.

As of today (2025-04-09), Lee's Pharmaceutical Holdings's WACC % is 7.12%. Lee's Pharmaceutical Holdings's ROC % is 2.54% (calculated using TTM income statement data). Lee's Pharmaceutical Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Lee's Pharmaceutical Holdings ROC % Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings ROC % Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.14 -6.38 1.90 -0.20 2.41

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.23 1.58 0.70 3.75 1.12

Lee's Pharmaceutical Holdings ROC % Calculation

Lee's Pharmaceutical Holdings's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-7.359 * ( 1 - 35.2% )/( (2355.523 + 2489.78)/ 2 )
=-4.768632/2422.6515
=-0.20 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2782.028 - 424.975 - ( 189.301 - max(0, 650.104 - 651.634+189.301))
=2355.523

Lee's Pharmaceutical Holdings's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=94.19 * ( 1 - 10.21% )/( (2489.78 + 2020.871)/ 2 )
=84.573201/2255.3255
=3.75 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2548.712 - 463.722 - ( 194.985 - max(0, 632.641 - 696.76+194.985))
=2020.871

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lee's Pharmaceutical Holdings  (HKSE:00950) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Lee's Pharmaceutical Holdings's WACC % is 7.12%. Lee's Pharmaceutical Holdings's ROC % is 2.54% (calculated using TTM income statement data). Lee's Pharmaceutical Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Lee's Pharmaceutical Holdings ROC % Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lee's Pharmaceutical Holdings Business Description

Traded in Other Exchanges
N/A
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
Executives
Lion River I N.v. 2201 Interest of corporation controlled by you
Li Zhenfu 2201 Interest of corporation controlled by you
Assicurazioni Generali Spa 2201 Interest of corporation controlled by you
Leelalertsuphakun Wanee 2101 Beneficial owner
Huang Zuie-chin 2201 Interest of corporation controlled by you
Lue Shuk Ping Vicky 2202 Interest of your spouse
Li Xiaoyi 2101 Beneficial owner
Lee Siu Fong 2101 Beneficial owner
Ubs Group Ag 2201 Interest of corporation controlled by you
Panacea Venture Healthcare Fund Ii, L.p. 2101 Beneficial owner
Panacea Innovation Limited 2201 Interest of corporation controlled by you
Guang Dong Min Ying Tou Zi Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Apta Finance Sa 2201 Interest of corporation controlled by you
Qualister Sa 2101 Beneficial owner
Paponi Claudia 2202 Interest of your spouse

Lee's Pharmaceutical Holdings Headlines

No Headlines